» Articles » PMID: 15531750

Ventilation Inhomogeneities in Relation to Standard Lung Function in Patients with Cystic Fibrosis

Overview
Specialty Critical Care
Date 2004 Nov 9
PMID 15531750
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Based on serial lung function measurements performed in 142 children (68 males; 74 females) with cystic fibrosis (CF), prospectively evaluated over an age range of 6 to 20 years, we attempted to determine whether the lung clearance index (LCI) as a measure of ventilation inhomogeneities could be a discriminating factor of disease progression. Annual follow-up lung function measurements featuring FRC determined by whole-body plethysmography and multibreath nitrogen washouts, effective specific airway resistance, flow-volume curves, LCI, and gas exchange characteristics were analyzed by linear mixed-model analysis and Kaplan-Meier statistics. The earliest occurring and strongest factor of progression was the LCI, followed by maximal expiratory flow (MEF(50)) and FRC determined by plethysmography (p < 0.0001). Associations between onset of chronic Pseudomonas aeruginosa infection and CF transmembrane conductance regulator (CFTR) genotype with FEV(1) (p = 0.027) and FVC (p = 0.007) were identified. The study shows that the LCI predicts earlier in life and represented much better functional progression than FEV(1). Moreover, there is no single functional predictor of progression in CF, but aside from risk factors, such as onset of chronic P. aeruginosa infection and genotype, pulmonary hyperinflation, airway obstruction, and ventilation inhomogeneities are important pathophysiologic processes that should be evaluated concomitantly as determinants of lung progression in CF.

Citing Articles

Multimeric, multivalent fusion carrier proteins for site-selective glycoconjugate vaccines simultaneously targeting and .

Sorieul C, Mikladal B, Wu D, Brogioni B, Giovani C, Adamo G Chem Sci. 2025; .

PMID: 40041805 PMC: 11875126. DOI: 10.1039/d4sc08622h.


Lung Clearance Index Improves in People with Cystic Fibrosis not Achieving a Clinical Important Difference in Forced Expiratory Volume in One Second After Elexacaftor/Tezacaftor/Ivacaftor Therapy.

Dacco V, Gramegna A, Rosazza C, Mariani A, Biffi A, Lanfranchi C Lung. 2024; 203(1):9.

PMID: 39614886 DOI: 10.1007/s00408-024-00768-1.


Multiple-breath washout to detect lung disease in patients with inborn errors of immunity.

Busack L, Thee S, Liu Y, Allomba C, Ziegahn N, Tosolini A ERJ Open Res. 2024; 10(2).

PMID: 38469376 PMC: 10926008. DOI: 10.1183/23120541.01019-2023.


Assessment of functional diversities in patients with Asthma, COPD, Asthma-COPD overlap, and Cystic Fibrosis (CF).

Kraemer R, Baty F, Smith H, Minder S, Gallati S, Brutsche M PLoS One. 2024; 19(2):e0292270.

PMID: 38377145 PMC: 10878531. DOI: 10.1371/journal.pone.0292270.


Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis.

Xu W, Wu T, Zhou Z, Zuo Z Front Pharmacol. 2024; 14:1275470.

PMID: 38186649 PMC: 10768559. DOI: 10.3389/fphar.2023.1275470.